

Agreement 6: Hepatitis C Cure-based Payment Model

Parties: LiverTech Pharmaceuticals and Spanish National Health Service Country: Spain Disease Area: Hepatitis C (Genotypes 1-4) Agreement Overview: This innovative cure-based agreement addresses Spain's public health initiative to eliminate Hepatitis C by 2030. The contract provides access to direct-acting antivirals for approximately 8,500 patients annually, with payment fundamentally tied to achieving sustained virologic response (SVR). The agreement includes special provisions for difficult-to-treat populations including those with cirrhosis, HIV co-infection, and prior treatment failures.

Financial Structure:

- Initial payment: €15,000 per treatment course upon therapy initiation
- Success-based payment: Additional €22,000 only upon confirmed sustained virologic response (SVR12)
- Population-level metric: 5% discount if cure rate exceeds 95% across treated population (current clinical trial data suggests 93-97% SVR rates)
- Non-responder management: Free retreatment with alternative regimen if initial therapy fails
- Budget impact protection: Monthly patient initiation caps (725 new patients monthly) to control expenditure
- Annual price review based on total patients treated (volume-based adjustments of 3-8% discount at predefined thresholds)
- Regional equity provision: Guaranteed minimum treatment slots for each autonomous community based on disease prevalence
- Special population bonus: €3,500 additional payment for achieving SVR in patients with decompensated cirrhosis

Duration: 2 years with option for 2-year extension Special Provisions:

- Includes screening program funding (€4.3 million annually) targeting high-risk populations
- Liver fibrosis assessment through transitional elastography (FibroScan)
- Patient identification registry to prevent loss to follow-up
- Specialized pharmacy network for medication distribution
- Healthcare provider education program on optimal therapy management
- Post-cure surveillance protocol for patients with advanced fibrosis
- Data collection system for national hepatitis registry
- Community outreach program for marginalized populations